Clinical Trials in the UK / NCT07049926
Recruiting
Phase 1/2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Renal Cell Carcinoma
Investigational drug(s) / intervention(s)
Belzutifan: Oral Tablet
Zanzalintinib: Oral Tablet
Study summary
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy.
This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study
Eligibility
The main inclusion criteria include but are not limited to the following:
* Has a histologically confirmed diagnosis of unresectable locally advanced/metastatic renal cell carcinoma (RCC) with clear cell component
* Has received no other prior systemic therapy for treatment of advanced/metastatic clear cell renal cell carcinoma (ccRCC) except for adjuvant programmed cell death ligand 1 (PD-(L)1) therapy
* Has disease recurrence during adjuvant anti- PD-(L)1 therapy or ≤24 months following the last dose of adjuvant anti-PD-(L)1 therapy
* Is able to swallow oral medication
* Submits an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
* Participants receiving bone resorptive therapy (must have therapy initiated at least 2 weeks before allocation/randomization)
* Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤140/90 mm Hg with no change in antihypertensive medications within 1 week before allocation/randomization
* Has adequate organ function
The main exclusion criteria include but are not limited to the following:
* Has clinically significant hematuria, hematemesis, or hemoptysis of (\>2.5 mL) of red blood, or other history of significant bleeding
* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
* Has deep vein thrombosis within 3 months before allocation/randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before allocation/randomization
* Has history of idiopathic pulmonary fibrosis, organizing pneumonia, or evidence of active pneumonitis
* Has serious wound, ulcer or bone fracture or has had major surgery within 8 weeks before first dose of study intervention
* Has symptomatic pleural effusion (for example cough, dyspnea, pleuritic chest pain), ascites, or pericardial fluid requiring drainage in the last 4 weeks before allocation/randomization
* Has gastrointestinal (GI) disorders, including those associated with a high risk of perforation or fistula formation
* Has malabsorption due to prior GI surgery or GI disease
* Has moderate to severe hepatic impairment
* Has received colony-stimulating factors within 28 days prior to intervention allocation/randomization
* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
* Is currently receiving strong inhibitors of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of the study
* Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention
* Is currently receiving anticoagulants or platelet inhibitors that cannot be discontinued for the duration of the study
* Have been previously allocated/randomized to study intervention in any sub study of protocol MK-3475-U03
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation
* Has active autoimmune disease that has required systemic treatment in the past 2 years
* Has an active infection requiring systemic therapy
* Has history of human immunodeficiency virus (HIV) infection
* Has hepatitis B or hepatitis C virus infection
Primary outcome measure(s)
- Safety Lead In Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs) — Up to approximately 21 days
DLTs are defined as any of a pre-specified list of toxicities if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration, excluding toxicities clearly not related to the drug, such as disease progression, environmental factors, unrelated trauma, etc. - Safety Lead In Phase: Number of participants who experience one or more adverse events (AEs) — Up to approximately 74 months
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. - Safety Lead In Phase: Number of participants who discontinue study treatment due to an AE — Up to approximately 74 months
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. - Efficacy Phase: Number of participants who experience one or more DLTs — Up to approximately 21 days
DLTs are defined as any of a pre-specified list of toxicities if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration, excluding toxicities clearly not related to the drug, such as disease progression, environmental factors, unrelated trauma, etc. - Efficacy Phase: Number of participants who experience one or more AEs — Up to approximately 74 months
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. - Efficacy Phase: Number of participants who discontinue study treatment due to an AE — Up to approximately 74 months
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. - Efficacy Phase: Objective Response Rate (ORR) — Up to approximately 74 months
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.
Trial sites (33)
| Facility | City | Region | Status |
|---|---|---|---|
| UCSF Medical Center at Mission Bay ( Site 5008) | San Francisco | California | Recruiting |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026) | Mineola | New York | Recruiting |
| Laura and Isaac Perlmutter Cancer Center ( Site 5016) | New York | New York | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 5002) | New York | New York | Recruiting |
| Duke Cancer Institute ( Site 5015) | Durham | North Carolina | Recruiting |
| UPMC Cancer Center/Hillman Cancer Center ( Site 5017) | Pittsburgh | Pennsylvania | Recruiting |
| Vanderbilt University Medical Center ( Site 5004) | Nashville | Tennessee | Recruiting |
| Centro de Estudios Clínicos SAGA ( Site 6110) | Santiago | Region M. de Santiago | Recruiting |
| CDIEM ( Site 6114) | Santiago | Region M. de Santiago | Recruiting |
| Bradfordhill ( Site 6101) | Santiago | Region M. de Santiago | Recruiting |
| C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203) | Strasbourg | Bas-Rhin | Recruiting |
| Institut Claudius Regaud ( Site 5200) | Toulouse | Haute-Garonne | Recruiting |
| Centre Eugene Marquis ( Site 5205) | Rennes | Ille-et-Vilaine | Recruiting |
| Institut De Cancerologie De Lorraine ( Site 5204) | Vandœuvre-lès-Nancy | Meurthe-et-Moselle | Recruiting |
| Gustave Roussy ( Site 5202) | Villejuif | Île-de-France Region | Recruiting |
| Rambam Health Care Campus ( Site 5500) | Haifa | Israel | Recruiting |
| Rabin Medical Center ( Site 5502) | Petah Tikva | Israel | Recruiting |
| Sheba Medical Center ( Site 5501) | Ramat Gan | Israel | Recruiting |
| Sourasky Medical Center ( Site 5503) | Tel Aviv | Israel | Recruiting |
| Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 6201) | Bydgoszcz | Kuyavian-Pomeranian Voivodeship | Recruiting |
| Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie ( Site 6203) | Warsaw | Masovian Voivodeship | Recruiting |
| Uniwersyteckie Centrum Kliniczne ( Site 6202) | Gdansk | Pomeranian Voivodeship | Recruiting |
| Severance Hospital ( Site 5802) | Seoul | South Korea | Recruiting |
| Asan Medical Center ( Site 5800) | Seoul | South Korea | Recruiting |
| Samsung Medical Center ( Site 5801) | Seoul | South Korea | Recruiting |
| HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 5302) | Madrid | Madrid, Comunidad de | Recruiting |
| Hospital Universitario Ramon y Cajal ( Site 5301) | Madrid | Madrid, Comunidad de | Recruiting |
| Hospital Universitari Vall d'Hebron ( Site 5300) | Barcelona | Spain | Recruiting |
| Western General Hospital ( Site 5402) | Edinburgh | Edinburgh, City of | Recruiting |
| The Beatson West of Scotland Cancer Centre ( Site 5405) | Glasgow | Glasgow City | Recruiting |
| St Bartholomew's Hospital ( Site 5401) | London | London, City of | Recruiting |
| Velindre Cancer Centre ( Site 5407) | Cardiff | United Kingdom | Recruiting |
| The Christie NHS Foundation Trust ( Site 5400) | Manchester | United Kingdom | Recruiting |
More Merck Sharp & Dohme LLC trials in the UK
Other trials for the same condition
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Active, not recruiting
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07049926 on ClinicalTrials.gov ↗ ← All trials in the UK